Determining sources of workplace contamination with antineoplastic drugs and comparing conventional IV drug preparation with a closed system

Hospital Pharmacy

Volumn 38, Issue 2, 2003, Pages 135-139

  Spivey, Susan ^a   Connor, Thomas H ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antineoplastic drugs; Closed system; Environmental contamination; Fluorescein

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORESCEIN;

ARTICLE; DRUG ABSORPTION; DRUG CONTAMINATION; DRUG EXPOSURE; ENVIRONMENTAL EXPOSURE; HEALTH HAZARD; INDWELLING CATHETER; NEEDLE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PHARMACY; SYRINGE; WORKPLACE;

EID: 0037329046     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870303800213     Document Type: Article

References (26)

1. Baker ES, Connor TH. Monitoring occupational exposure to cancer chemotherapy drugs. Am J Health Syst Pharm. 1996;53:2713-23.
2. Sorsa M, Anderson D. Monitoring of occupational exposure to cytostatic anticancer agents. Mutat Res. 1996;355:253-61.
3. Bos RP, Sessink PJ. Biomonitoring of occupational exposure to cytostatic anticancer drugs. Rev Environ Health. 1997;12:43-58.
4. Sessink PJ, Bos RP. Drugs hazardous to healthcare workers: Evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Saf. 1999; 20;347-59.
5. McDevitt JJ, Lees PSJ, McDiarmid, MA. Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med. 1993;35:57-60.
6. Sessink PJM, Boer KA, Scheefhals APH, et al. Occupational exposure to antineoplastic agents at several departments in a hospital: Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health. 1992;64:105-12.
7. Sessink PJ, Anzion RB, Van den Broek PHH, et al. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci. 1992;14:16-22.
8. Sessink PJ, Van de Kerkhof MC, Anzion RB, et al. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: Is skin absorption an important exposure route? Arch Environ Health. 1994;49:165-9.
9. Connor TH, Anderson, RW, Sessink PJ, et al. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health Syst Pharm. 1999;56:1427-32.
10. Minoia C, Turci R, Sottani C, et al. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commum Mass Spectrom. 1998;12:1485-93.
11. Rubino FM, Floridia L, Pietropaolo AM, et al. Measurement of surface contamination by certain antineoplastic drugs using high-performance liquid chromatography: Applications in occupational hygiene investigations in hospital environments. Med Lav. 1999;90:572-83.
12. Connor, TH, Anderson RW, Sessink PJ. Intervention study to reduce occupational exposure to antineoplastic agents in a pharmacy setting. Internat Pharmaceut Abs. 1999;36:2194.
13. Connor, TH, Anderson RW, Sessink PJ, et al. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an IV admixture area. Am J Health Syst Pharm. 2002;59:68-72.
14. Vandenbroucke J, Robays H. How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Practice. 2001;6:146-52.
15. Jackson MA, Stack HF, Waters MD. Genetic activity profiles of anticancer drugs. Mutat Res. 1996;355:171-208.
16. Valanis B, Vollmer W, Labuhn K, et al. Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists. J Occup Environ Med. 1997;39:574-80.
17. Valanis B, Vollmer WM, Steele P. Occupational exposure to antineoplastic agents: Self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med. 1999;41:632-8.
18. International Agency for Research on Cancer. http://www.iarc.fr.
19. Nguyen TV, Theiss JC, Matney TS. Exposure of pharmacy personnel to mutagenic antineoplastic drugs. Cancer Res. 1982;42:4792-6.
20. Anderson RW, Puckett WH, Dana WJ, et al. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm. 1982;39:1881-7.
21. Carmel Pharma ab. http://www.carmelpharma.se.
22. Sessink PJ, Rolf M-AE, Rydèn NS. Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm. 1999;34:1311-7.
23. Kendall LTP. Chemochek Training Kits. http://www.kendallltp.com.
24. Harrison BR, Godefroid RJ, et al. Quality-assurance testing of staff pharmacists handling cytotoxic agents. Am J Health Syst Pharm. 1996;53:402-7.
25. Kromhout H, Hoek F, Uitterhoeve R, et al. Postulating a dermal pathway for exposure to antineoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann Occup Hyg. 2000;44:551-60.
26. Sessink PJM, Kroese ED, van Kranen HJ, et al. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health. 1995;67: 317-23.